Pyxis Oncology, Inc.

What they do

Pyxis Oncology is a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients with solid tumors, with an immediate focus on head and neck squamous cell carcinoma (HNSCC). Its lead product candidate, MICVO (formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B of fibronectin (EDB+FN), a structural component of the tumor extracellular matrix. MICVO is being studied as monotherapy in recurrent and metastatic HNSCC and in combination with KEYTRUDA (pembrolizumab) in 1L/2L+ R/M HNSCC and other solid tumors. The company has no approved products and is not generating product revenue.

Revenue drivers

• MICVO monotherapy — Lead clinical program being evaluated in R/M HNSCC; no product revenue and no approved product.
• MICVO plus pembrolizumab combination — Phase 1/2 dose escalation study in 1L R/M HNSCC; clinical-stage only, no revenue.
• Reported revenue — Annual revenue was $16.1M in 2024 and $13.9M in 2025; the nature of this revenue is not described in the provided excerpts.

Recent performance

Annual revenue was $16.1M in 2024 and $13.9M in 2025, while net loss was $77.3M in 2024 and $79.6M in 2025. Operating cash flow was -$57.7M in 2024 and -$63.5M in 2025. At June 30, 2026, total assets were $54.9M, total liabilities were $43.5M, shareholder equity was $11.4M, and cash and equivalents were $18.9M. In August 2026, the company reported second quarter 2026 financial results and said it completed a private placement financing for up to $114 million, with approximately $50 million in upfront gross proceeds, extending its cash runway into the second quarter of 2027.

Strategy

The company is focused on advancing MICVO through clinical development in HNSCC, both as monotherapy and in combination with pembrolizumab. It completed target enrollment in the Phase 1 Part 2 monotherapy dose expansion study in the first quarter of 2026. In December 2025, a dose cap was implemented for higher body weight patients, and future monotherapy disclosures will focus on patients treated at or below the dose cap. The company raised up to $114 million in a private placement to fund additional patient follow-up and key clinical milestones. Management has stated it remains focused on generating clinical evidence to evaluate MICVO's potential in head and neck cancer regardless of HPV status or prior therapy.

Risks

• Clinical-stage with no approved products — MICVO is investigational and has not received regulatory approval, so the company has no product revenue and depends on clinical success.
• Substantial and recurring losses — Net losses were $77.3M in 2024 and $79.6M in 2025, and operating cash flow was negative $63.5M in 2025.
• Limited cash runway — As of June 30, 2026, cash and equivalents were $18.9M, and the company has stated its cash runway extends into the second quarter of 2027.
• Dilution from financing — The July 2026 private placement for up to $114 million included warrants that, if exercised, would result in additional shares and potential dilution.

Outlook

Management expects to report updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC in Fall 2026, including analyses of the dose cap's impact on safety, tolerability, efficacy, and initial durability. Updated data from the Phase 1/2 combination study with pembrolizumab in 1L R/M HNSCC is expected in the fourth quarter of 2026. The company reported that its cash runway extends into the second quarter of 2027.